Levomilnacipran for the Treatment of Major Depressive Disorder

Total Page:16

File Type:pdf, Size:1020Kb

Levomilnacipran for the Treatment of Major Depressive Disorder Out of the Pipeline Levomilnacipran for the treatment of major depressive disorder Matthew Macaluso, DO, Hala Kazanchi, MD, and Vikram Malhotra, MD An SNRI with n July 2013, the FDA approved levomil- Table 1 once-daily dosing, nacipran for the treatment of major de- Levomilnacipran: Fast facts levomilnacipran pressive disorder (MDD) in adults.1 It is I Brand name: Fetzima decreased core available in a once-daily, extended-release formulation (Table 1).1 The drug is the fifth Class: Serotonin-norepinephrine reuptake symptoms of inhibitor serotonin-norepinephrine reuptake inhibi- MDD and was well Indication: Treatment of major depressive tor (SNRI) to be sold in the United States disorder in adults tolerated in clinical and the fourth to receive FDA approval for FDA approval date: July 26, 2013 trials treating MDD. Availability date: Fourth quarter of 2013 Levomilnacipran is believed to be the Manufacturer: Forest Pharmaceuticals more active enantiomer of milnacipran, Dosage forms: Extended–release capsules in which has been available in Europe for 20 mg, 40 mg, 80 mg, and 120 mg strengths years and was approved by the FDA in Recommended dosage: 40 mg to 120 mg 2009 for treating fibromyalgia. Efficacy of capsule once daily with or without food levomilnacipran for treating patients with Source: Reference 1 MDD was established in three 8-week ran- domized controlled trials (RCTs).1 cial and occupational functioning in addi- Clinical implications tion to improvement in the core symptoms Levomilnacipran is indicated for treating of depression.5 MDD in adults and is unique compared Levomilnacipran is the more active en- with other SNRIs because it is relatively antiomer of milnacipran, an SNRI that is more selective for norepinephrine reuptake approved for treating fibromyalgia in the inhibition (NRI) compared with serotonin United States and approved for treating reuptake inhibition (SRI).1 In vitro stud- depression in many other countries.6 In ies demonstrate that the drug has >10-fold general, enantiomeric formulations are greater selectivity for norepinephrine reup- believed to have advantages over racemic take inhibition than it does for serotonin formulations because they are less com- reuptake inhibition, compared with dulox- etine or venlafaxine.2 Dr. Macaluso is Assistant Professor, Director of Research and Associate This difference in selectivity could Director of Residency Training, and Drs. Kazanchi and Malhotra are Senior Residents, University of Kansas School of Medicine-Wichita, lend itself to treating symptoms of MDD Wichita, Kansas. that might be related to norepinephrine Disclosures deficiency; these include decreased con- Dr. Macaluso has been the principal investigator in clinical trials for AbbVie, Eisai, Envivo, Janssen, Naurex, and Pfizer. All clinical trial centration, lassitude, mental and physical and study contracts and payments were made through the Kansas slowing, and decreased self-care.3,4 Some University Medical Center Research Institute. Drs. Kazanchi and Malhotra report no financial relationship with any company whose authors claim that individual patients Current Psychiatry products are mentioned in this article or with manufacturers of 50 December 2013 could experience improvement in their so- competing products. Out of the Pipeline plex and have a more selective pharmaco- it susceptible to DDIs with drugs that in- dynamic profile, better therapeutic index, hibit or induce this enzyme. For example, lower liability for drug-drug interactions a person taking levomilnacipran with a (DDIs), and a less complicated relation- potent CYP3A4 inhibitor, such as keto- ship between plasma concentration and conazole, may require a dosage adjust- pharmacodynamic effect.6 In addition, ment. No dosage adjustment is needed regulatory guidelines in the United States when given with a CYP3A4 inducer or recommend development of enantiomers substrate. Drinking alcohol with levomil- over racemates where appropriate.7 nacipran may cause more rapid release of the drug into the blood stream.1 How it works Levomilnacipran’s exact mechanism of ac- Efficacy tion is unknown. Similar to other SNRIs, Levomilnacipran decreased core symp- it binds with high affinity to the serotonin toms of MDD and showed a statistically Clinical Point (5-HT) and norepinephrine (NE) trans- significant separation from placebo in 2 Levomilnacipran is porters and potently inhibits 5-HT and NE phase III RCTs (Table 2, page 54).3,5 The first reuptake. Levomilnacipran lacks signifi- study was a 10-week flexible dose (75 or suitable for once-daily cant affinity for any other receptors, ion 100 mg) trial in 563 outpatients age 18 to dosing; maximum channels, or transporters tested in vitro.2 70 who met DSM-IV-TR criteria of MDD plasma concentration It differs from other SNRIs such as ven- for >1 month and had a 17-item Hamilton is 6 to 8 hours, and lafaxine and duloxetine in having higher Depression Rating Scale (HDRS-17) score the drug has a half-life selectivity for norepinephrine vs serotonin >22 and a Sheehan Disability Scale (SDS) reuptake inhibition. In vitro studies dem- score >10.3 The primary efficacy mea- of 12 hours onstrated a 2-fold preference for NE over sure was change in Montgomery-Åsberg 5-HT reuptake inhibition.2 Depression Rating Scale (MADRS) score from baseline to week 10. Secondary ef- Pharmacokinetics ficacy measures included the HDRS-17, Levomilnacipran reaches maximum plas- SDS, and Clinical Global Impressions- ma concentration within 6 to 8 hours of improvement scale. Efficacy analyses in- oral administration and has a half-life of cluded 276 subjects treated with levomil- approximately 12 hours, which makes it nacipran and 277 treated with placebo.3 suitable for once-daily dosing. The concen- Levomilnacipran was significant- tration of levomilnacipran at steady state ly superior to placebo on the MADRS is proportional to the dosage of the drug and HDRS-17 from baseline to week when administered within the range of 25 10. Response and remission rates were to 300 mg once daily.1 significantly greater for the levomil- The drug’s mean apparent total clear- nacipran group compared with pla- ance is 21 to 29 liters/hour and its bioavail- cebo. Response exceeded the 10% aver- ability is not significantly affected when age advantage for drug vs placebo and taken with food. The drug is widely dis- 46% of levomilnacipran-treated patients tributed in the body and is converted pri- achieved remission.3 marily to 2 metabolites: desethyl levomil- The number needed to treat (NNT), nacipran and p-hydroxy-levomilnacipran. based on the MADRS scores for the levo- Discuss this article at Both metabolites are inactive and undergo milnacipran group compared with the pla- www.facebook.com/ CurrentPsychiatry further conjugation with glucuronide. cebo group, was 6 for response and 5 for The drug is eliminated primarily via renal remission.3 By comparison, most studies of excretion.1 venlafaxine demonstrate a NNT of 8.3 The major enzyme that catalyzes me- Levomilnacipran generally was report- tabolism of levomilnacipram is cyto- ed to be safe and well tolerated. The most Current Psychiatry chrome P 450 (CYP) 3A4, which makes common adverse events leading to discon- Vol. 12, No. 12 51 Out of the Pipeline tinuation in the levomilnacipran group the number of patients reporting adverse were nausea, vomiting, change in systolic events and who discontinued participa- and diastolic blood pressure, and increase tion because of adverse events was higher in heart rate. The favorable tolerability in the 80-mg group than in the 40-mg and profile of levomilnacipran may relate to 120-mg groups.5 the 2-fold greater potency for NE reuptake inhibition compared with 5-HT reuptake Tolerability inhibition.3 Overall, levomilnacipran was well toler- The second study was an 11-week, ated in clinical trials, during which 2,673 fixed-dose trial of levomilnacipran using subjects were exposed to the drug— 40, 80, or 120 mg. A total of 724 outpatients translating to 942 patient-years of expo- age 18 to 65 who met DSM-IV-TR criteria sure. These patients ranged in age from for MDD and who had an ongoing episode 18 to 78; 825 of these subjects were enrolled Clinical Point of depression lasting >8 weeks were ran- in long-term studies for 1 year. Dosing of Levomilnacipran domly assigned to receive placebo (n = 179) levomilnacipran during these studies or levomilnacipran at 40 mg (n = 181), ranged from 40 to 120 mg once daily, with- was well tolerated 80 mg (n = 181), or 120 mg (n = 183) once out regard to food.1 in clinical trials; 9% daily for 8 weeks of double-blind treat- Nine percent of patients who received of patients who ment followed by a 2-week, double-blind levomilnacipran in short-term studies dis- received the drug taper of the drug.5 The primary efficacy continued because of adverse events, com- parameter was change from baseline on pared with 3% of patients who received discontinued because the MADRS and the secondary efficacy placebo. The most common adverse event of adverse events parameter was change from baseline in reported was nausea; other common ad- SDS total score. HDRS-17, CGI-I, and verse events reported included constipa- CGI-S were included as secondary out- tion, hyperhidrosis, elevated heart rate, come measures.5 erectile dysfunction, tachycardia, palpita- Significant difference in MADRS total tions, and vomiting. Of these events, only score were seen in the levomilnacipran erectile dysfunction and urinary hesita- group compared with the placebo group tion were dose-related.1 Among levo- (least mean squared difference: 40 mg/d, milnacipran-treated female patients, <2% −3.23; 80 mg/d, −3.99; and 120 mg/d, reported adverse events related to sexual −4.86). Higher dosages produced a numer- dysfunction. ically greater change and significant sepa- All SNRIs have well established associa- ration from placebo occurred sooner in the tions with elevation in blood pressure and 80-mg and 120-mg groups compared with heart rate.
Recommended publications
  • Concomitant Drugs Associated with Increased Mortality for MDMA Users Reported in a Drug Safety Surveillance Database Isaac V
    www.nature.com/scientificreports OPEN Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database Isaac V. Cohen1, Tigran Makunts2,3, Ruben Abagyan2* & Kelan Thomas4 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). If MDMA is FDA-approved it will be important to understand what medications may pose a risk of drug– drug interactions. The goal of this study was to evaluate the risks due to MDMA ingestion alone or in combination with other common medications and drugs of abuse using the FDA drug safety surveillance data. To date, nearly one thousand reports of MDMA use have been reported to the FDA. The majority of these reports include covariates such as co-ingested substances and demographic parameters. Univariate and multivariate logistic regression was employed to uncover the contributing factors to the reported risk of death among MDMA users. Several drug classes (MDMA metabolites or analogs, anesthetics, muscle relaxants, amphetamines and stimulants, benzodiazepines, ethanol, opioids), four antidepressants (bupropion, sertraline, venlafaxine and citalopram) and olanzapine demonstrated increased odds ratios for the reported risk of death. Future drug–drug interaction clinical trials should evaluate if any of the other drug–drug interactions described in our results actually pose a risk of morbidity or mortality in controlled medical settings. 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Adminis- tration (FDA) for the treatment of posttraumatic stress disorder (PTSD). During the past two decades, “ecstasy” was illegally distributed and is purported to contain MDMA, but because the market is unregulated this “ecstasy” may actually contain adulterants or no MDMA at all1.
    [Show full text]
  • Canadian Stroke Best Practice Recommendations
    CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS MOOD, COGNITION AND FATIGUE FOLLOWING STROKE Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression Update 2019 Lanctôt KL, Swartz RH (Writing Group Chairs) on Behalf of the Canadian Stroke Best Practice Recommendations Mood, Cognition and Fatigue following Stroke Writing Group and the Canadian Stroke Best Practice and Quality Advisory Committee, in collaboration with the Canadian Stroke Consortium © 2019 Heart & Stroke Heart and Stroke Foundation Mood, Cognition and Fatigue following Stroke Canadian Stroke Best Practice Recommendations Table 1C Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on selected classes of medications available for use in Canada and more commonly recommended for post-stroke depression. This table should be used as a reference guide by health care professionals when selecting an appropriate agent for individual patients. Patient compliance, patient preference and/or past experience, side effects, and drug interactions should all be taken into consideration during decision-making, in addition to other information provided in this table and available elsewhere regarding these medications. Selective Serotonin Reuptake Inhibitors (SSRI) Serotonin–norepinephrine reuptake Other inhibitors (SNRI) Medication *citalopram – Celexa *duloxetine – Cymbalta methylphenidate – Ritalin (amphetamine)
    [Show full text]
  • Methylphenidate Hydrochloride
    Application for Inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE December 7, 2018 Submitted by: Patricia Moscibrodzki, M.P.H., and Craig L. Katz, M.D. The Icahn School of Medicine at Mount Sinai Graduate Program in Public Health New York NY, United States Contact: [email protected] TABLE OF CONTENTS Page 3 Summary Statement Page 4 Focal Point Person in WHO Page 5 Name of Organizations Consulted Page 6 International Nonproprietary Name Page 7 Formulations Proposed for Inclusion Page 8 International Availability Page 10 Listing Requested Page 11 Public Health Relevance Page 13 Treatment Details Page 19 Comparative Effectiveness Page 29 Comparative Safety Page 41 Comparative Cost and Cost-Effectiveness Page 45 Regulatory Status Page 48 Pharmacoepial Standards Page 49 Text for the WHO Model Formulary Page 52 References Page 61 Appendix – Letters of Support 2 1. Summary Statement of the Proposal for Inclusion of Methylphenidate Methylphenidate (MPH), a central nervous system (CNS) stimulant, of the phenethylamine class, is proposed for inclusion in the WHO Model List of Essential Medications (EML) & the Model List of Essential Medications for Children (EMLc) for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) under ICD-11, 6C9Z mental, behavioral or neurodevelopmental disorder, disruptive behavior or dissocial disorders. To date, the list of essential medications does not include stimulants, which play a critical role in the treatment of psychotic disorders. Methylphenidate is proposed for inclusion on the complimentary list for both children and adults. This application provides a systematic review of the use, efficacy, safety, availability, and cost-effectiveness of methylphenidate compared with other stimulant (first-line) and non-stimulant (second-line) medications.
    [Show full text]
  • Print Your Symptom Diary
    MEDICATION GUIDE FETZIMA® (fet-ZEE-muh) (levomilnacipran) extended-release capsules, for oral use What is the most important information I should know about FETZIMA? FETZIMA may cause serious side effects, including: • Increased risk of suicidal thoughts or actions in some children, adolescents, and young adults. FETZIMA and other antidepressant medicines may increase suicidal thoughts or actions in some children and young adults, especially within the first few months of treatment or when the dose is changed. FETZIMA is not for use in children. o Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression, bipolar illness (also called manic-depressive illness) or have a history of suicidal thoughts or actions. How can I watch for and try to prevent suicidal thoughts and actions? o Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions. This is very important when an antidepressant medicine is started or when the dose is changed. o Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. o Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. Call your healthcare provider or
    [Show full text]
  • Preferred Drug List Illinois Medicaid 10/1/2019: Revised 11/06/2019 for Drugs Not Found on This List, Go to the Drug Search Engine At
    Preferred Drug List Illinois Medicaid 10/1/2019: Revised 11/06/2019 For drugs not found on this list, go to the drug search engine at: www.ilpriorauth.com *Exceptions as noted above* ▪ADHD Agents: Prior authorization required for participants under 6 years of age and participants 19 years of age and older ▪Spiriva AER 1.25mcg: Prior authorization NOT required for participants ages 6-17 years ▪Budesonide: Prior authorization NOT required for participants age 7 years and under ▪Anticonvulsants: Prior authorization NOT required for non-preferred epilepsy agents for those participants with a diagnosis of epilepsy or seizure disorder in Department records ▪Antipsychotics: Prior authorization required for participants under 8 years of age and long- term care residents 1 of 27 Preferred Drug List Illinois Medicaid 10/1/2019: Revised 11/06/2019 For drugs not found on this list, go to the drug search engine at: www.ilpriorauth.com Category Preferred Preferred, Requires PA Non-Preferred ADHD Agent - Amphetamine Mixtures* AMPHETAMINE/DEXTROAMPHETAMINE ADDERALL ADDERALL XR MYDAYIS ADHD Agent - Amphetamines* VYVANSE ADZENYS ER ADZENYS XR-ODT AMPHETAMINE SULFATE DESOXYN DEXEDRINE DEXTROAMPHETAMINE SULFATE DEXTROAMPHETAMINE SULFATE ER DYANAVEL XR EVEKEO EVEKEO ODT METHAMPHETAMINE HCL PROCENTRA ZENZEDI ADHD Agent - Selective Alpha Adrenergic Agonists CLONIDINE HCL ER INTUNIV CLONIDINE HYDROCHLORIDE ER GUANFACINE ER ADHD Agent - Selective Norepinephrine Reuptake Inhibitor* ATOMOXETINE ATOMOXETINE HYDROCHLORIDE STRATTERA 2 of 27 Preferred Drug List Illinois
    [Show full text]
  • Levomilnacipran (Fetzima®) Indication
    Levomilnacipran (Fetzima®) Indication: Indicated for the treatment of major depressive disorder (MDD), FDA approved July 2013. Mechanism of action Levomilnacipran, the more active enantiomer of racemic milnacipran, is a selective SNRI with greater potency for inhibition of norepinephrine relative to serotonin reuptake Compared with duloxetine or venlafaxine, levomilnacipran has over 10-fold higher selectivity for norepinephrine relative to serotonin reuptake inhibition The exact mechanism of the antidepressant action of levomilnacipran is unknown Dosage and administration Initial: 20 mg once daily for 2 days and then increased to 40 mg once daily. The dosage can be increased by increments of 40 mg at intervals of two or more days Maintenance: 40-120 mg once daily with or without food. Fetzima should be swallowed whole (capsule should not be opened or crushed) Levomilnacipran and its metabolites are eliminated primarily by renal excretion o Renal impairment Dosing: Clcr 30-59 mL/minute: 80 mg once daily Clcr 15-29 mL/minute: 40 mg once daily End-stage renal disease (ESRD): Not recommended Discontinuing treatment: Gradually taper dose, if intolerable withdrawal symptoms occur, consider resuming the previous dose and/or decrease dose at a more gradual rate How supplied: Capsule ER 24 Hour Fetzima Titration: 20 & 40 mg (28 ea) Fetzima: 20 mg, 40 mg, 80 mg, 120 mg Warnings and Precautions Elevated Blood Pressure and Heart Rate: measure heart rate and blood pressure prior to initiating treatment and periodically throughout treatment Narrow-angle glaucoma: may cause mydriasis. Use caution in patients with controlled narrow- angle glaucoma Urinary hesitancy or retention: advise patient to report symptoms of urinary difficulty Discontinuation Syndrome Seizure disorders: Use caution with a previous seizure disorder (not systematically evaluated) Risk of Serotonin syndrome when taken alone or co-administered with other serotonergic agents (including triptans, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone, and St.
    [Show full text]
  • Premium Non-Specialty Quantity Limit List January 2016
    Premium Non-Specialty Quantity Limit List January 2016 Therapeutic Category Drug Name Dispensing Limit Anti-infectives Antibiotics DIFICID (fidaxomicin) 200 mg 2 tabs/day & 10 days/30 days SIVEXTRO (tedizolid) Solr 6 vials/30 days SIVEXTRO (tedizolid) Tabs 6 tabs/30 days ZYVOX (linezolid) 28 tabs/30 days ZYVOX (linezolid) Suspension 4 bottles (600 mL)/28 days Antifungals LAMISIL (terbinafine) 250 mg 84 days supply/180 days Antimalarial QUALAQUIN (quinine) QL varies* Antivirals, Herpetic FAMVIR (famciclovir) 125 mg 1 tab/day FAMVIR (famciclovir) 250 mg 2 tabs/day FAMVIR (famciclovir) 500 mg 21 tabs/30 days SITAVIG (acyclovir) 50 mg 2 tabs/30 days VALTREX (valacyclovir) 1000 mg 3 tabs/day VALTREX (valacyclovir) 500 mg 2 tabs/day Antivirals, Influenza RELENZA (zanamivir) QL is 40 inh per 365 days. TAMIFLU (oseltamivir) 30 mg 40 caps per 365 days TAMIFLU (oseltamivir) 45 mg, 75 mg 20 caps per 365 days TAMIFLU (oseltamivir) Suspension 360 mL/365 days Cardiology Anticoagulants ELIQUIS (apixiban) 2 tabs/day ELIQUIS (apixiban) 5 mg 3 tabs/day IPRIVASK (desirudin) 35 days supply/180 days PRADAXA (dabigatran) 2 caps/day SAVAYSA (edoxaban) 1 tab/day XARELTO (rivaroxaban) 10 mg 35 days supply/180 days XARELTO (rivaroxaban) 15 mg 2 tabs/day XARELTO (rivaroxaban) 20 mg 1 tab/day XARELTO (rivaroxaban) Starter Pack 2 starter packs/year Heart Failure CORLANOR (ivabradine) 2 tabs/day Central Nervous System ADHD Agents ADDERALL (amphetamine/dextroamphetamine) 3 tabs/day ADDERALL XR (amphetamine/dextroamphetamine mixed salts) 1 cap/day APTENSIO XR (methylphenidate)
    [Show full text]
  • Sibutramine Hydrochloride Monohydrate) Capsule CS-IV
    MERIDIA - sibutramine hydrochloride capsule ---------- MERIDIA® (sibutramine hydrochloride monohydrate) Capsule CS-IV DESCRIPTION MERIDIA® (sibutramine hydrochloride monohydrate) is an orally administered agent for the treatment of obesity. Chemically, the active ingredient is a racemic mixture of the (+) and (-) enantiomers of cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, hydrochloride, monohydrate, and has an empirical formula of C17H29Cl2NO. Its molecular weight is 334.33. The structural formula is shown below: Sibutramine hydrochloride monohydrate is a white to cream crystalline powder with a solubility of 2.9 mg/mL in pH 5.2 water. Its octanol: water partition coefficient is 30.9 at pH 5.0. Each MERIDIA capsule contains 5 mg, 10 mg, and 15 mg of sibutramine hydrochloride monohydrate. It also contains as inactive ingredients: lactose monohydrate, NF; microcrystalline cellulose, NF; colloidal silicon dioxide, NF; and magnesium stearate, NF in a hard-gelatin capsule [which contains titanium dioxide, USP; gelatin; FD&C Blue No. 2 (5- and 10-mg capsules only); D&C Yellow No. 10 (5- and 15-mg capsules only), and other inactive ingredients]. CLINICAL PHARMACOLOGY Mode of Action Sibutramine produces its therapeutic effects by norepinephrine, serotonin and dopamine reuptake inhibition. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines. Pharmacodynamics Sibutramine exerts its pharmacological actions predominantly via its secondary (M1) and primary (M2) amine metabolites. The parent compound, sibutramine, is a potent inhibitor of serotonin (5- hydroxytryptamine, 5-HT) and norepinephrine reuptake in vivo, but not in vitro. However, metabolites M1 and M2 inhibit the reuptake of these neurotransmitters both in vitro and in vivo.
    [Show full text]
  • Pristiq (Desvenlafaxine Succinate) – First-Time Generic
    Pristiq® (desvenlafaxine succinate) – First-time generic • On March 1, 2017, Teva launched AB-rated generic versions of Pfizer’s Pristiq (desvenlafaxine succinate) 25 mg, 50 mg, and 100 mg extended-release tablets for the treatment of major depressive disorder. — Teva launched the 25 mg tablet with 180-day exclusivity. — In addition, Alembic/Breckenridge, Mylan, and West-Ward have launched AB-rated generic versions of Pristiq 50 mg and 100 mg extended-release tablets. — Greenstone’s launch plans for authorized generic versions of Pristiq 25 mg, 50 mg, and 100 mg tablets are pending. — Lupin and Sandoz received FDA approval of AB-rated generic versions of Pristiq 50 mg and 100 mg tablets on June 29, 2015. Lupin’s and Sandoz’s launch plans are pending. • Other serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder include desvenlafaxine fumarate, duloxetine, Fetzima™ (levomilnacipran), Khedezla™ (desvenlafaxine) , venlafaxine, and venlafaxine extended-release. • Pristiq and the other serotonin-norepinephrine reuptake inhibitors carry a boxed warning for suicidal thoughts and behaviors. • According to IMS Health data, the U.S. sales of Pristiq were approximately $883 million for the 12 months ending on December 31, 2016. optumrx.com OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com. All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners. This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.
    [Show full text]
  • Milnacipran Remediates Impulsive Deficits in Rats with Lesions of the Ventromedial Prefrontal Cortex
    Title Milnacipran Remediates Impulsive Deficits in Rats with Lesions of the Ventromedial Prefrontal Cortex Author(s) Tsutsui-Kimura, Iku; Yoshida, Takayuki; Ohmura, Yu; Izumi, Takeshi; Yoshioka, Mitsuhiro International journal of neuropsychopharmacology, 18(5), pyu083 Citation https://doi.org/10.1093/ijnp/pyu083 Issue Date 2015-03 Doc URL http://hdl.handle.net/2115/59283 Rights(URL) http://creativecommons.org/licenses/by-nc/4.0 Type article File Information pyu083.full.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP International Journal of Neuropsychopharmacology, 2015, 1–14 doi:10.1093/ijnp/pyu083 Research Article research article Milnacipran Remediates Impulsive Deficits in Rats with Lesions of the Ventromedial Prefrontal Cortex Iku Tsutsui-Kimura, PhD; Takayuki Yoshida, PhD; Yu Ohmura, PhD; Takeshi Izumi, MD, PhD; Mitsuhiro Yoshioka, MD, PhD Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Sapporo, Japan (Drs Tsutsui-Kimura, Yoshida, Ohmura, Izumi, and Yoshioka); Japan Society for the Promotion of Science, Tokyo, Japan (Dr Tsutsui-Kimura); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Dr Tsutsui-Kimura). Correspondence: Yu Ohmura, PhD, Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, N15 W7, Kita-ku, Sapporo, 060-8638, Japan ([email protected]). Abstract Background: Deficits in impulse control are often observed in psychiatric disorders in which abnormalities of the prefrontal cortex are observed, including attention-deficit/hyperactivity disorder and bipolar disorder. We recently found that milnacipran, a serotonin/noradrenaline reuptake inhibitor, could suppress impulsive action in normal rats. However, whether milnacipran could suppress elevated impulsive action in rats with lesions of the ventromedial prefrontal cortex, which is functionally comparable with the human prefrontal cortex, remains unknown.
    [Show full text]
  • A Brief Overview of Psychiatric Pharmacotherapy
    A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures • Some medications discussed are not approved by the FDA for use in the population discussed/described. • Some medications discussed are not approved by the FDA for use in the manner discussed/described. • Co-Owner: – PrairieCare and PrairieCare Medical Group – Catch LLC Disclaimer The contents of this handout are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical or psychiatric condition. Never disregard professional/medical advice or delay in seeking it because of something you have read in this handout. Material in this handout may be copyrighted by the author or by third parties; reasonable efforts have been made to give attribution where appropriate. Caveat Regarding the Role of Medication… Neuroscience Overview Mind Over Matter, National Institute on Drug Abuse, National Institutes of Health. Available at: http://teens.drugabuse.gov/mom/index.asp. http://medicineworld.org/images/news-blogs/brain-700997.jpg Neuroscience Overview Mind Over Matter, National Institute on Drug Abuse, National Institutes of Health. Available at: http://teens.drugabuse.gov/mom/index.asp. Neurotransmitter Receptor Source: National Institute on Drug Abuse Common Diagnoses and Associated Medications • Psychotic Disorders – Antipsychotics • Bipolar Disorders – Mood Stabilizers, Antipsychotics, & Antidepressants • Depressive Disorders – Antidepressants • Anxiety Disorders – Antidepressants & Anxiolytics • Attention Deficit Hyperactivity Disorder – Stimulants, Antidepressants, 2-Adrenergic Agents, & Strattera Classes of Medications • Anti-depressants • Stimulants and non-stimulant alternatives • Anti-psychotics (a.k.a.
    [Show full text]
  • CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology
    CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology Generic Name (Brand Name) Cidofovir (Vistide) Acetaminophen/butalbital (Allzital; Citalopram (Celexa) Bupap) Clomipramine (Anafranil) Acetaminophen/butalbital/caffeine Clonidine (Catapres; Kapvay) (Fioricet; Butace) Clorazepate (Tranxene-T) Acetaminophen/butalbital/caffeine/ Clozapine (Clozaril; FazaClo; Versacloz) codeine (Fioricet with codeine) Cyclizine (No Brand Name) Acetaminophen/caffeine (Excedrin) Cyclobenzaprine (Flexeril) Acetaminophen/caffeine/dihydrocodeine Desipramine (Norpramine) (Panlor; Trezix) Desvenlafaxine (Pristiq; Khedezla) Acetaminophen/tramadol (Ultracet) Dexmethylphenidate (Focalin) Aliskiren (Tekturna) Dextroamphetamine (Dexedrine; Amitriptyline (Elavil) ProCentra; Zenzedi) Amitriptyline and chlordiazepoxide Dextroamphetamine and amphetamine (Limbril) (Adderall) Amoxapine (Asendin) Diazepam (Valium; Diastat) Aripiprazole (Abilify) Diethylpropion (No Brand Name) Armodafinil (Nuvigil) Dimenhydrinate (Dramamine) Asenapine (Saphris) Donepezil (Aricept) Aspirin/caffeine (BC Powder; Goody Doripenem (Doribax) Powder) Doxapram (Dopram) Atomoxetine (Strattera) Doxepin (Silenor) Baclofen (Gablofen; Lioresal) Droperidol (No Brand Name) Benzphetamine (Didrex; Regimex) Duloxetine (Cymbalta) Benztropine (Cogentin) Entacapone (Comtan) Bismuth Ergotamine and caffeine (Cafergot; subcitrate/metronidazole/tetracycline Migergot) (Pylera) Escitalopram (Lexapro) Bismuth subsalicylate (Pepto-Bismol) Fluoxetine (Prozac; Sarafem)
    [Show full text]